The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
August 6th 2025
The FDA targets 7-hydroxymitragynine, a potent kratom derivative, as a controlled substance due to its opioid-like effects and rising health risks.
FDA Issues New Labeling Changes Clarifying Safety of Testosterone Products Following Clinical Trials
March 4th 2025The FDA is issuing new changes to labels on testosterone products, clarifying that there are no increases in major cardiac events among men with hypogonadism but noting an increase in blood pressure with the use of such products.
Read More